Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Pfizer/BioNTech, Moderna Submit Omicron EUAs For Fall Season

Executive Summary

Under FDA guidance, the companies submitted clinical data for BA.1-targeting bivalent vaccines together with BA.4/BA.5 preclinical data. Novavax got a nod for its COVID-19 vaccine in adolescents, but its own Omicron development efforts remain behind the two mRNA heavyweights.

You may also be interested in...



Moderna Lauds Joint Work With Health Authorities On Spikevax Safety Monitoring

A senior executive at Moderna recounts how the company used a variety of data sources to identify potential safety signals for its Spikevax COVID-19 vaccine during a state of “hyper-pharmacovigilance.”

Valneva Confirms Step Back From COVID-19 Vaccine Development

The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.

Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business

Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel